Developer docs
API playgroundTry for free, no card

Search company profiles

Beacon Biosignals

Full company profile

uuid0000ann

Namestring
Beacon Biosignals
Legal namestring
Beacon Biosignals, Inc.
Websiteurl
beacon.bio
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Beacon Biosignals, founded in 2019 and headquartered in Boston, operates an end-to-end precision neuroscience platform that combines an FDA 510(k)-cleared at-home EEG headband (Waveband, formerly Dreem 3S) with a cloud-native data layer (Beacon Datastore), an analytics and trial management portal (Beacon HQ), AI/ML sleep staging (SleepStage ML), a Bluetooth-paired patient companion app (Beacon Pal), and full-service clinical study operations and scientific services teams. The platform is the first sleep wearable authorized under an FDA Predetermined Change Control Plan (PCCP), enabling continuous algorithm updates without new 510(k) submissions, and is supported by a proprietary foundation model of brain activity trained on millions of hours of EEG across a Clinico-EEG database containing data from nearly 100,000 patients. Beacon serves two distinct customer segments: (1) biopharmaceutical R&D teams — including Takeda, Harmony Biosciences, UCB, Longboard Pharmaceuticals, Skye Bioscience, and Syndeio, with the company claiming R&D program support for more than half of the world's top ten biopharma — who pay under multi-year enterprise data licensing and milestone structures (e.g., up to $109M in potential Takeda data license fees and milestones), and (2) sleep physicians, neurologists, and primary care providers, served through the SleepView Monitor, SleepView Direct mail-order fulfillment, and SleepView Web Portal acquired from CleveMed in April 2025 and rebranded under Beacon in June 2026. Revenue mechanics span enterprise subscription/analytics access, bundled HST per-study plans (Gold and Silver), device hardware sales, and milestone-based licensing with strategic biopharma partners.

Short descriptiontext

Beacon Biosignals operates an AI-powered precision neuroscience platform combining an FDA-cleared at-home EEG headband with cloud analytics, serving biopharmaceutical sponsors running CNS clinical trials and healthcare providers delivering home sleep testing.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
EEG analytics platform, at-home sleep monitoring, CNS clinical trials, home sleep testing, brain health biomarkers
Industry5 codes
PRIMARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGADAH
Cell-Based & Potency Assays (Bioassays)
SECONDARYHLACAFAL
Connected Therapeutics & Smart Drug Delivery Monitoring
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHLACANAF
SaMD – Digital Biomarkers & Algorithmic Endpoints
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
NAICS code3 codes
  • Medical and Diagnostic Laboratories6215
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code3 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Commercial Physical & Biological Research8731
Product category
Neurotechnology & Brain Health Analytics
Social media profiles2 records
GTM motion5 records

Each record includes

Type, Description, Source

Revenue model5 records
1SleepView Direct bundled study pricing
TypeTransaction Fee
Description

Mail-order home sleep testing offered under Gold and Silver bundled per-study plans that include the SleepView Monitor, Web Portal access, shipping/handling, disposable accessories, patient phone support, and (Gold) RPSGT manual scoring. Sold primarily to sleep centers and providers.

beacon.bio
2SleepView Monitor hardware + SleepView Web Portal subscription
TypeHardware Sales
Description

Sale or deployment of the SleepView Monitor device plus recurring access to the HIPAA-compliant SleepView Web Portal (file management, automated respiratory event scoring, EMR integrations, complimentary upgrades and support). Optional CPAP connector, thermistor, second effort belt, and ID Check accessories.

3Biopharma data licensing and milestone payments (Takeda model)
TypeLicensing Royalties
Description

Multi-year data-license agreements with development, regulatory, and commercial milestones plus equity participation. Example: expanded Takeda collaboration in which Beacon is eligible to receive up to $109 million in data license fees and milestones. Effectively a licensing/royalty-plus-milestone revenue stream from CNS drug developers.

beacon.bio
4Clinical Study Operations and Scientific Services (professional services)
TypeProfessional Services
Description

Full-service clinical trial support including device deployment/logistics, low-latency compliance monitoring, site and user training, integrated data solutions, scientific endpoint advice, biostatistics and signal-processing analyses, and translational medicine / biomarker discovery. Typically bundled with biopharma EEG biomarker programs.

beacon.bio
5Beacon Platform enterprise analytics (Datastore + Beacon HQ)
TypeSubscription Recurring
Description

Enterprise access to the Beacon Datastore and Beacon HQ analytics portal — centralized EEG data storage, AI-powered analytics, dataset drill-downs, regulatory dataset downloads, and event monitoring — typically delivered under enterprise agreements with biopharma sponsors.

beacon.bio
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain
Pricing details4 tiers
1SleepView Direct Gold plan: bundled per-study HST including the SleepView Monitor, Web Portal, shipping, accessories, patient support, and RPSGT manual scoring.
ModelOtherBilling cadencePay-as-you-go
Notes

Bundled study pricing — specific price not publicly disclosed. Designed for sleep centers seeking fully managed mail-order HST including manual scoring.

beacon.bio
2SleepView Direct Silver plan: bundled per-study HST with self-administered scoring (no RPSGT manual scoring by default).
ModelOtherBilling cadencePay-as-you-go
Notes

Bundled study pricing — specific price not publicly disclosed. Lower tier than Gold, used for the SleepView Direct Silver walk-through workflow.

beacon.bio
3Enterprise/quote-based pricing for the Beacon Platform (Waveband, Datastore, Beacon HQ, Clinical Study Operations, Scientific Services) sold to biopharma sponsors.
ModelOtherBilling cadenceMulti-year contract
Notes

Not publicly disclosed; multi-year licensing and milestone structures (e.g., up to $109M in data license fees and milestones from Takeda).

beacon.bio
4Reimbursement context for SleepView: CPT 95800, 95806, and HCPCS G0399 with common ICD-10 codes such as G47.33 (obstructive sleep apnea).
ModelOtherBilling cadencePay-as-you-go
Notes

Provided as a reimbursement coding reference for providers, not as company list pricing. Coverage and allowable amounts vary by payor (Aetna, Anthem, Cigna, Humana, United, Medicare).

beacon.bio
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 7 records shown
1Waveband
Description

FDA 510(k)-cleared at-home EEG headband (formerly Dreem 3S) that collects PSG-quality sleep EEG data for clinical trials and home use.

beacon.bio
+6 more records
Core offering1 text field

Beacon Biosignals provides an end-to-end precision neuroscience platform that combines an FDA 510(k)-cleared at-home EEG headband (Waveband, formerly Dreem 3S) with a cloud-native AI/ML analytics stack (Beacon Datastore, Beacon HQ, SleepStage ML) and proprietary brain-activity foundation models to deliver EEG biomarkers, quantitative endpoints, and sleep diagnostics for CNS drug development and clinical care. The platform supports Phase 1-4 clinical trials for biopharmaceutical sponsors and is paired with a home sleep testing business (SleepView Monitor, SleepView Direct, SleepView Web Portal) acquired from CleveMed that serves sleep physicians, neurologists, and primary care providers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 10 values shown
  • 2M+ hours of EEG analyzed on the Beacon Platform
+9 more records
Product overview1 text field

Beacon Biosignals operates an end-to-end precision neuroscience platform that combines an FDA 510(k)-cleared wearable EEG device (Waveband, formerly Dreem 3S) with an AI-driven analytics stack to capture and analyze sleep brain data at home for both clinical trials and clinical care. The platform is built around the Beacon Datastore (data and analytics layer), Beacon HQ (trial management and analytics portal), and Beacon Scientific/Clinical Study Operations services, with Beacon Pal as the patient-facing companion app. On top of this, Beacon offers a Sleep Diagnostics business acquired from CleveMed — including the SleepView Monitor (Type III home sleep testing device), SleepView Direct (mail-order HST fulfillment), and the HIPAA-compliant SleepView Web Portal with EMR integration — which was formally unified under the Beacon brand in June 2026. AI capabilities (proprietary foundation model trained on millions of hours of EEG; FDA-cleared SleepStage ML; automated arousal detection; epileptiform activity characterization) power biomarker discovery for CNS drug development across partnerships with companies including Takeda, Harmony Biosciences, UCB, and more than half of the world's top ten biopharmaceutical companies.

Product and service10 records
1Waveband (formerly Dreem 3S)
CategoryFDA-cleared wearable EEG device / Core platform hardware
Description

FDA 510(k)-cleared (K223539) at-home EEG headband that directly records the brain's electrical activity during sleep and wake. Equipped with 5 EEG channels (frontal F7/F8, ground Fp1, occipital O1/O2) and a 3-axis accelerometer for head movement, head position, and respiratory trace; over 24-hour battery life; raw EDF output; and Bluetooth pairing with the Beacon Pal app. PSG-equivalent sleep staging validated as performing as well as or better than human experts.

2Beacon Pal
CategoryPatient-facing companion mobile app
Description

Mobile companion app that pairs with the Waveband via Bluetooth for patient-initiated EEG recordings. Offers customizable self-report questionnaires, supports six different languages, performs real-time sensor-placement verification, and transmits data over a secure, encrypted, version-controlled connection. Designed to enable caregiver or patient setup without a technologist.

3Beacon Datastore
CategoryCore platform — biosignal data and analytics layer
Description

Cloud-native data management and analytics layer of the Beacon Platform. Stores millions of hours of biosignal data with version control, integrated Beacon Analytics (510(k)-cleared ML algorithms for PSG analysis, epileptiform activity characterization, standardized spectral analysis), low-latency event monitoring, third-party data integration, tokenization for privacy-preserving joins, and SOC 2 Type 2 security with US DPF / GDPR compliance and GCP-compliant retention.

4Beacon HQ
CategoryCore platform — analytics and trial management portal
Description

Web portal that gives clinical development teams a window into the Beacon Datastore for organizing, exploring, and analyzing EEG datasets across clinical trials. Capabilities include data drill-downs by cohort/demographic/site, blinded trial site compliance monitoring, regulatory documentation export, and team data sharing/integration with external data systems.

5Beacon Clinical Study Operations
CategoryProfessional services — clinical trial operations
Description

Full-service team supporting device deployment, logistics, setup, low-latency compliance monitoring, data quality review, site/user training on the Beacon Pal app and study technology, and data transfer agreements to incorporate patient-reported outcomes throughout Phase 1-4 clinical trials.

6Beacon Scientific Services
CategoryProfessional services — scientific analysis and biomarker discovery
Description

Expert team providing scientific strategy, endpoint advisory, measurement frequency guidance, comprehensive reporting, translational medicine interpretation, and retrospective/real-world data biomarker discovery analysis. Expertise spans neuroscience, biostatistics, signal processing, electrical engineering, and data science.

7SleepStage ML
CategoryAI-powered sleep staging software (FDA-cleared)
Description

FDA 510(k)-cleared AI-powered sleep staging software that performs automated sleep staging from EEG signals, validated to perform equivalent to or better than human expert scorers. Used in conjunction with the Waveband (Dreem 3S) headband and supports the PCCP-authorized continuous algorithm enhancement pathway.

8SleepView Monitor
CategoryFDA-cleared Type III home sleep testing device
Description

Small, lightweight FDA-cleared Type III (also meets Type IV) HST device with 8 channels: heart rate, pulse oximetry, respiratory airflow (compatible with CPAP via cannula port up to 20 cm H2O), RIP respiratory effort belt, snore, body position, auxiliary channel, and integrated actigraphy for Total Sleep Time. Dimensions 3" x 2.6" x 0.7", 2 oz, powered by 1 AAA battery. Meets AASM and CMS clinical guidelines; SleepView Web Portal supports automated respiratory event scoring and EMR integration. 97% patient acceptance rate.

9SleepView Direct
CategoryMail-order home sleep testing fulfillment service
Description

Mail-order home sleep testing fulfillment program that lets sleep centers and providers scale HST services without adding staff. Includes the SleepView Monitor, customized kit preparation, outbound and return shipping logistics, dedicated patient phone support, customizable reports through the SleepView Web Portal, and optional RPSGT manual scoring (Gold plan) with board-certified sleep physician over-read. Plans: Gold and Silver.

10SleepView Web Portal
CategoryHIPAA-compliant cloud-based HST management software
Description

HIPAA-compliant, AASM-compliant web-based platform for centralized home sleep study management. Provides secure online access to every sleep study, automated respiratory event scoring, automatic data upload on device check-in, lifecycle admin access, centralized scoring, online reports, automatic email notifications, and SleepView Direct order management. Integrates with provider EMRs.

Scale indicator16 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierFlagship / Strategic CoreTypeStrategic or Co-development PartnerAnnounced on2025-12-16
Description

Collaboration to incorporate Beacon's Waveband EEG headband and AI-driven quantitative EEG algorithms into two of Harmony's Phase 3 studies of HBS-301 for Narcolepsy and Idiopathic Hypersomnia. Combines traditional patient-reported outcomes (e.g., Epworth Sleepiness Scale) with objective EEG data across consecutive nights of sleep and daytime naps. Aims to enable more robust characterization of daytime and nighttime sleep patterns and to identify EEG biomarkers for dose selection and efficacy assessment.

Strategic tierFlagship / Strategic CoreTypeStrategic or Co-development PartnerAnnounced on2025-11-19
Description

Multi-year expansion (Nov 2025) of Beacon's strategic collaboration with Takeda to accelerate data-driven development of sleep biomarkers and new diagnostic pathways for narcolepsy. Uses Beacon's FDA-cleared at-home EEG headband (Waveband) and AI analytics to shorten the diagnostic journey for narcolepsy NT1 patients. Beacon is eligible to receive up to $109M in data license fees plus development, regulatory, and commercial milestones, including equity participation. Builds on the original 2024 partnership.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-13
Description

Named biopharma partner among Beacon's R&D collaborators leveraging AI-derived biomarkers for CNS drug development, patient selection, and precision medicine.

Strategic tierFlagship / Strategic CoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-04-21
Description

Beacon Biosignals acquired CleveMed (a Home Sleep Testing technology and services provider) in a strategic transaction to enhance sleep testing technology and expand market access. CleveMed's SleepView and SleepView Direct home testing service were subsequently unified under the Beacon brand (announced June 2026), combining CleveMed's home sleep testing infrastructure with Beacon's AI-driven brain monitoring technology. The integrated platform is described by Beacon as the most advanced EEG-based home sleep testing platform in the U.S.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-12-12
Description

Collaboration on the HEADFIRST study of sleep architecture in children with LGS using Beacon's Dreem 3S EEG headband. Findings presented at AES 2024 (REM sleep 56.77 min LGS vs 104.34 min controls; mean sleep cycles 4.6 LGS vs 2.6 controls). UCB also named among Beacon's biopharma R&D partners leveraging AI-derived biomarkers.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-12-12
Description

Collaboration on the Dreem LGS Caregiver Study using Beacon's FDA-cleared Dreem 3S EEG headband to characterize sleep disturbances in caregivers of children with LGS. Caregivers showed significantly higher Wake After Sleep Onset (37.79 min vs 24.70 min in controls).

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-18
Description

Partner on the HEADFIRST basket study evaluating the Dreem 3S/Waveband headband in pediatric patients with neurodevelopmental disorders, beginning with Lennox-Gastaut Syndrome (LGS). LGS Foundation supports recruitment and awareness for the first cohorts.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-07-25
Description

Strategic collaboration to integrate sleep quality and sleep apnea endpoints using Beacon's at-home EEG and AI platform into Skye's CBEYOND Phase 2 trial of nimacimab for obesity.

Strategic tierFlagship / Strategic CoreTypeStrategic or Co-development PartnerAnnounced on2023-07-11
Description

Beacon acquired Dreem's research and development business on July 11, 2023, integrating Dreem's FDA-cleared at-home sleep monitoring hardware with Beacon's AI EEG analytics platform. The transaction included an undisclosed Series A financing round led by General Catalyst. Dreem was a Paris-based sleep monitoring pioneer founded in 2014 with $57M+ prior funding.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight8 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Wearable biosignal (ECG) patch with cloud-native AI analytics and a service-based diagnostic offering. Closely comparable business model to Beacon: FDA-cleared wearable + AI/ML algorithms + cloud platform + enterprise payer/provider sales, and an adjacent biosignal category (cardiac vs. brain).

TypeBroad incumbent
Description

Global sleep diagnostics and neurophysiology hardware and software company. Direct overlap with Beacon's SleepView/EEG business: PSG, HST, and EEG systems sold to sleep labs, hospitals, and research sites, with attached software and scoring services.

TypeDirect peer
Description

AI-powered point-of-care EEG and seizure detection platform sold to hospitals and clinical sites. Comparable to Beacon in the AI-on-EEG regulatory pathway (FDA-cleared algorithms, cloud-based interpretation) and in bringing objective brain biomarkers into routine clinical care.

TypeDirect peer
Description

Wearable actigraphy and digital endpoint platform used in clinical trials and academic research. Comparable to Beacon on the wearable + cloud + clinical-trial endpoint axis, particularly for sleep and activity biomarkers, though without direct EEG measurement.

TypeBroad incumbent
Description

Sleep diagnostics hardware and software (PSG, HSAT, AURA) company with strong presence in sleep labs and HST providers. Comparable to Beacon's home and lab sleep testing stack, particularly the CleveMed/SleepView business, and increasingly to Beacon's cloud platform strategy.

TypeDirect peer
Description

Multi-day, at-home EEG assessment platform purpose-built for CNS clinical trials. Directly comparable to Beacon's life sciences business: similar goal of replacing in-clinic EEG/PSG with remote, longitudinal brain-activity data for pharma-led trials in psychiatry and neurology.

TypeBroad incumbent
Description

Long-established neurodiagnostics and sleep diagnostics device maker with a broad portfolio of EEG, PSG, and HST hardware. Comparable to the CleveMed/SleepView side of Beacon in clinical-channel neurodiagnostic hardware, and to Beacon's PSG/EEG algorithm stack through Natus' competing clinical offerings.

TypeDirect peer
Description

Digital cognitive assessment and CNS clinical trial endpoint company serving biopharma. Comparable to Beacon's life sciences side as a vendor of objective, scalable brain/CNS endpoints (cognitive rather than EEG, but the same biopharma R&D buyer and biomarker-discovery value proposition).

TypeBroad incumbent
Description

Alphabet-owned precision health and sleep/brain health business (including the Verily Study Watch and earlier sleep efforts). Comparable to Beacon in its ambition to build a multi-modal, at-home, AI-driven brain/cardiac data platform for clinical research, but with vastly larger capital and distribution.

TypeBroad incumbent
Description

Home sleep testing and cardiology diagnostics (WatchPAT) provider acquired by ZOLL/ResMed. Closely comparable to CleveMed/SleepView in the at-home HST category and to Beacon's direct-to-provider sleep diagnostics channel, with similar reimbursement and sleep physician buyer profiles.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability9 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature11 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors16 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Beacon Biosignals

Neurotechnology & Brain Health Analyticsbeacon.bio

Beacon Biosignals operates an AI-powered precision neuroscience platform combining an FDA-cleared at-home EEG headband with cloud analytics, serving biopharmaceutical sponsors running CNS clinical trials and healthcare providers delivering home sleep testing.

What Beacon Biosignals does

Beacon Biosignals, founded in 2019 and headquartered in Boston, operates an end-to-end precision neuroscience platform that combines an FDA 510(k)-cleared at-home EEG headband (Waveband, formerly Dreem 3S) with a cloud-native data layer (Beacon Datastore), an analytics and trial management portal (Beacon HQ), AI/ML sleep staging (SleepStage ML), a Bluetooth-paired patient companion app (Beacon Pal), and full-service clinical study operations and scientific services teams. The platform is the first sleep wearable authorized under an FDA Predetermined Change Control Plan (PCCP), enabling continuous algorithm updates without new 510(k) submissions, and is supported by a proprietary foundation model of brain activity trained on millions of hours of EEG across a Clinico-EEG database containing data from nearly 100,000 patients. Beacon serves two distinct customer segments: (1) biopharmaceutical R&D teams — including Takeda, Harmony Biosciences, UCB, Longboard Pharmaceuticals, Skye Bioscience, and Syndeio, with the company claiming R&D program support for more than half of the world's top ten biopharma — who pay under multi-year enterprise data licensing and milestone structures (e.g., up to $109M in potential Takeda data license fees and milestones), and (2) sleep physicians, neurologists, and primary care providers, served through the SleepView Monitor, SleepView Direct mail-order fulfillment, and SleepView Web Portal acquired from CleveMed in April 2025 and rebranded under Beacon in June 2026. Revenue mechanics span enterprise subscription/analytics access, bundled HST per-study plans (Gold and Silver), device hardware sales, and milestone-based licensing with strategic biopharma partners.

Beacon Biosignals firmographics

Firmographics
Name
Beacon Biosignals
Legal name
Beacon Biosignals, Inc.
Website
https://beacon.bio
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
101–250 employees
Short description
Beacon Biosignals operates an AI-powered precision neuroscience platform combining an FDA-cleared at-home EEG headband with cloud analytics, serving biopharmaceutical sponsors running CNS clinical trials and healthcare providers delivering home sleep testing.
Ownership category
akta.pro rank

Beacon Biosignals industry classification

Industry
Product category
Neurotechnology & Brain Health Analytics
NAICS
Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGADAH
Cell-Based & Potency Assays (Bioassays)
SECONDARYHLACAFAL
Connected Therapeutics & Smart Drug Delivery Monitoring
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHLACANAF
SaMD – Digital Biomarkers & Algorithmic Endpoints
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)

Keywords

  • EEG analytics platform
  • At-home sleep monitoring
  • CNS clinical trials
  • Home sleep testing
  • Brain health biomarkers

Where Beacon Biosignals is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Offices4 records

Markets served

Beacon Biosignals business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

  1. SleepView Direct bundled study pricing: Mail-order home sleep testing offered under Gold and Silver bundled per-study plans that include the SleepView Monitor, Web Portal access, shipping/handling, disposable accessories, patient phone support, and (Gold) RPSGT manual scoring. Sold primarily to sleep centers and providers.
  2. SleepView Monitor hardware + SleepView Web Portal subscription: Sale or deployment of the SleepView Monitor device plus recurring access to the HIPAA-compliant SleepView Web Portal (file management, automated respiratory event scoring, EMR integrations, complimentary upgrades and support). Optional CPAP connector, thermistor, second effort belt, and ID Check accessories.
  3. Biopharma data licensing and milestone payments (Takeda model): Multi-year data-license agreements with development, regulatory, and commercial milestones plus equity participation. Example: expanded Takeda collaboration in which Beacon is eligible to receive up to $109 million in data license fees and milestones. Effectively a licensing/royalty-plus-milestone revenue stream from CNS drug developers.
  4. Clinical Study Operations and Scientific Services (professional services): Full-service clinical trial support including device deployment/logistics, low-latency compliance monitoring, site and user training, integrated data solutions, scientific endpoint advice, biostatistics and signal-processing analyses, and translational medicine / biomarker discovery. Typically bundled with biopharma EEG biomarker programs.
  5. Beacon Platform enterprise analytics (Datastore + Beacon HQ): Enterprise access to the Beacon Datastore and Beacon HQ analytics portal — centralized EEG data storage, AI-powered analytics, dataset drill-downs, regulatory dataset downloads, and event monitoring — typically delivered under enterprise agreements with biopharma sponsors.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goSleepView Direct Gold plan: bundled per-study HST including the SleepView Monitor, Web Portal, shipping, accessories, patient support, and RPSGT manual scoring.
OtherPay-as-you-goSleepView Direct Silver plan: bundled per-study HST with self-administered scoring (no RPSGT manual scoring by default).
OtherMulti-year contractEnterprise/quote-based pricing for the Beacon Platform (Waveband, Datastore, Beacon HQ, Clinical Study Operations, Scientific Services) sold to biopharma sponsors.
OtherPay-as-you-goReimbursement context for SleepView: CPT 95800, 95806, and HCPCS G0399 with common ICD-10 codes such as G47.33 (obstructive sleep apnea).

Go-to-market motion5 records

Distribution channels4 records

Marketing channels9 records

Beacon Biosignals product offering

Product offering

Core offering

Beacon Biosignals provides an end-to-end precision neuroscience platform that combines an FDA 510(k)-cleared at-home EEG headband (Waveband, formerly Dreem 3S) with a cloud-native AI/ML analytics stack (Beacon Datastore, Beacon HQ, SleepStage ML) and proprietary brain-activity foundation models to deliver EEG biomarkers, quantitative endpoints, and sleep diagnostics for CNS drug development and clinical care. The platform supports Phase 1-4 clinical trials for biopharmaceutical sponsors and is paired with a home sleep testing business (SleepView Monitor, SleepView Direct, SleepView Web Portal) acquired from CleveMed that serves sleep physicians, neurologists, and primary care providers.

Product overview

Beacon Biosignals operates an end-to-end precision neuroscience platform that combines an FDA 510(k)-cleared wearable EEG device (Waveband, formerly Dreem 3S) with an AI-driven analytics stack to capture and analyze sleep brain data at home for both clinical trials and clinical care. The platform is built around the Beacon Datastore (data and analytics layer), Beacon HQ (trial management and analytics portal), and Beacon Scientific/Clinical Study Operations services, with Beacon Pal as the patient-facing companion app. On top of this, Beacon offers a Sleep Diagnostics business acquired from CleveMed — including the SleepView Monitor (Type III home sleep testing device), SleepView Direct (mail-order HST fulfillment), and the HIPAA-compliant SleepView Web Portal with EMR integration — which was formally unified under the Beacon brand in June 2026. AI capabilities (proprietary foundation model trained on millions of hours of EEG; FDA-cleared SleepStage ML; automated arousal detection; epileptiform activity characterization) power biomarker discovery for CNS drug development across partnerships with companies including Takeda, Harmony Biosciences, UCB, and more than half of the world's top ten biopharmaceutical companies.

Differentiator

Problem solved

Functional benefit

Brands

  • Waveband: FDA 510(k)-cleared at-home EEG headband (formerly Dreem 3S) that collects PSG-quality sleep EEG data for clinical trials and home use.
  • SleepView
  • SleepView Direct
  • Beacon Platform
  • Beacon Datastore
  • Beacon HQ
  • Beacon Pal

Products and services

  • Waveband (formerly Dreem 3S) FDA 510(k)-cleared (K223539) at-home EEG headband that directly records the brain's electrical activity during sleep and wake. Equipped with 5 EEG channels (frontal F7/F8, ground Fp1, occipital O1/O2) and a 3-axis accelerometer for head movement, head position, and respiratory trace; over 24-hour battery life; raw EDF output; and Bluetooth pairing with the Beacon Pal app. PSG-equivalent sleep staging validated as performing as well as or better than human experts.
  • Beacon Pal Mobile companion app that pairs with the Waveband via Bluetooth for patient-initiated EEG recordings. Offers customizable self-report questionnaires, supports six different languages, performs real-time sensor-placement verification, and transmits data over a secure, encrypted, version-controlled connection. Designed to enable caregiver or patient setup without a technologist.
  • Beacon Datastore Cloud-native data management and analytics layer of the Beacon Platform. Stores millions of hours of biosignal data with version control, integrated Beacon Analytics (510(k)-cleared ML algorithms for PSG analysis, epileptiform activity characterization, standardized spectral analysis), low-latency event monitoring, third-party data integration, tokenization for privacy-preserving joins, and SOC 2 Type 2 security with US DPF / GDPR compliance and GCP-compliant retention.
  • Beacon HQ Web portal that gives clinical development teams a window into the Beacon Datastore for organizing, exploring, and analyzing EEG datasets across clinical trials. Capabilities include data drill-downs by cohort/demographic/site, blinded trial site compliance monitoring, regulatory documentation export, and team data sharing/integration with external data systems.
  • Beacon Clinical Study Operations Full-service team supporting device deployment, logistics, setup, low-latency compliance monitoring, data quality review, site/user training on the Beacon Pal app and study technology, and data transfer agreements to incorporate patient-reported outcomes throughout Phase 1-4 clinical trials.
  • Beacon Scientific Services Expert team providing scientific strategy, endpoint advisory, measurement frequency guidance, comprehensive reporting, translational medicine interpretation, and retrospective/real-world data biomarker discovery analysis. Expertise spans neuroscience, biostatistics, signal processing, electrical engineering, and data science.
  • SleepStage ML FDA 510(k)-cleared AI-powered sleep staging software that performs automated sleep staging from EEG signals, validated to perform equivalent to or better than human expert scorers. Used in conjunction with the Waveband (Dreem 3S) headband and supports the PCCP-authorized continuous algorithm enhancement pathway.
  • SleepView Monitor Small, lightweight FDA-cleared Type III (also meets Type IV) HST device with 8 channels: heart rate, pulse oximetry, respiratory airflow (compatible with CPAP via cannula port up to 20 cm H2O), RIP respiratory effort belt, snore, body position, auxiliary channel, and integrated actigraphy for Total Sleep Time. Dimensions 3" x 2.6" x 0.7", 2 oz, powered by 1 AAA battery. Meets AASM and CMS clinical guidelines; SleepView Web Portal supports automated respiratory event scoring and EMR integration. 97% patient acceptance rate.
  • SleepView Direct Mail-order home sleep testing fulfillment program that lets sleep centers and providers scale HST services without adding staff. Includes the SleepView Monitor, customized kit preparation, outbound and return shipping logistics, dedicated patient phone support, customizable reports through the SleepView Web Portal, and optional RPSGT manual scoring (Gold plan) with board-certified sleep physician over-read. Plans: Gold and Silver.
  • SleepView Web Portal HIPAA-compliant, AASM-compliant web-based platform for centralized home sleep study management. Provides secure online access to every sleep study, automated respiratory event scoring, automatic data upload on device check-in, lifecycle admin access, centralized scoring, online reports, automatic email notifications, and SleepView Direct order management. Integrates with provider EMRs.

Quantifiable outcome

  • 2M+ hours of EEG analyzed on the Beacon Platform
  • +9 more outcomes

Companies that use Beacon Biosignals

Customer profile

Named customers7 records

Segments4 records

Ideal customer profiles3 records

Beacon Biosignals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability9 records

Feature11 records

Beacon Biosignals partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered flagship / strategic core and core.

  • Harmony Biosciencesflagship / strategic coreStrategic or Co-development Partner · 16 December 2025Collaboration to incorporate Beacon's Waveband EEG headband and AI-driven quantitative EEG algorithms into two of Harmony's Phase 3 studies of HBS-301 for Narcolepsy and Idiopathic Hypersomnia. Combines traditional patient-reported outcomes (e.g., Epworth Sleepiness Scale) with objective EEG data across consecutive nights of sleep and daytime naps. Aims to enable more robust characterization of daytime and nighttime sleep patterns and to identify EEG biomarkers for dose selection and efficacy assessment.
  • Takeda Pharmaceuticalflagship / strategic coreStrategic or Co-development Partner · 19 November 2025Multi-year expansion (Nov 2025) of Beacon's strategic collaboration with Takeda to accelerate data-driven development of sleep biomarkers and new diagnostic pathways for narcolepsy. Uses Beacon's FDA-cleared at-home EEG headband (Waveband) and AI analytics to shorten the diagnostic journey for narcolepsy NT1 patients. Beacon is eligible to receive up to $109M in data license fees plus development, regulatory, and commercial milestones, including equity participation. Builds on the original 2024 partnership.
  • SyndeiocoreStrategic or Co-development Partner · 13 November 2025Named biopharma partner among Beacon's R&D collaborators leveraging AI-derived biomarkers for CNS drug development, patient selection, and precision medicine.
  • CleveMedflagship / strategic coreOEM/ Whitelabel/ Licensing Partner · 21 April 2025Beacon Biosignals acquired CleveMed (a Home Sleep Testing technology and services provider) in a strategic transaction to enhance sleep testing technology and expand market access. CleveMed's SleepView and SleepView Direct home testing service were subsequently unified under the Beacon brand (announced June 2026), combining CleveMed's home sleep testing infrastructure with Beacon's AI-driven brain monitoring technology. The integrated platform is described by Beacon as the most advanced EEG-based home sleep testing platform in the U.S.
  • UCBcoreStrategic or Co-development Partner · 12 December 2024Collaboration on the HEADFIRST study of sleep architecture in children with LGS using Beacon's Dreem 3S EEG headband. Findings presented at AES 2024 (REM sleep 56.77 min LGS vs 104.34 min controls; mean sleep cycles 4.6 LGS vs 2.6 controls). UCB also named among Beacon's biopharma R&D partners leveraging AI-derived biomarkers.
  • Longboard PharmaceuticalscoreStrategic or Co-development Partner · 12 December 2024Collaboration on the Dreem LGS Caregiver Study using Beacon's FDA-cleared Dreem 3S EEG headband to characterize sleep disturbances in caregivers of children with LGS. Caregivers showed significantly higher Wake After Sleep Onset (37.79 min vs 24.70 min in controls).
  • LGS FoundationcoreStrategic or Co-development Partner · 18 September 2024Partner on the HEADFIRST basket study evaluating the Dreem 3S/Waveband headband in pediatric patients with neurodevelopmental disorders, beginning with Lennox-Gastaut Syndrome (LGS). LGS Foundation supports recruitment and awareness for the first cohorts.
  • Skye BiosciencecoreStrategic or Co-development Partner · 25 July 2024Strategic collaboration to integrate sleep quality and sleep apnea endpoints using Beacon's at-home EEG and AI platform into Skye's CBEYOND Phase 2 trial of nimacimab for obesity.
  • Dreem (R&D business)flagship / strategic coreStrategic or Co-development Partner · 11 July 2023Beacon acquired Dreem's research and development business on July 11, 2023, integrating Dreem's FDA-cleared at-home sleep monitoring hardware with Beacon's AI EEG analytics platform. The transaction included an undisclosed Series A financing round led by General Catalyst. Dreem was a Paris-based sleep monitoring pioneer founded in 2014 with $57M+ prior funding.

Scale indicators16 records

Recent moves6 records

Expansion highlights8 records

Beacon Biosignals competitors and assessment

Company assessment

Direct peers

  • iRhythm Technologies: Wearable biosignal (ECG) patch with cloud-native AI analytics and a service-based diagnostic offering. Closely comparable business model to Beacon: FDA-cleared wearable + AI/ML algorithms + cloud platform + enterprise payer/provider sales, and an adjacent biosignal category (cardiac vs. brain).
  • Ceribell: AI-powered point-of-care EEG and seizure detection platform sold to hospitals and clinical sites. Comparable to Beacon in the AI-on-EEG regulatory pathway (FDA-cleared algorithms, cloud-based interpretation) and in bringing objective brain biomarkers into routine clinical care.
  • ActiGraph: Wearable actigraphy and digital endpoint platform used in clinical trials and academic research. Comparable to Beacon on the wearable + cloud + clinical-trial endpoint axis, particularly for sleep and activity biomarkers, though without direct EEG measurement.
  • Cumulus Neuroscience: Multi-day, at-home EEG assessment platform purpose-built for CNS clinical trials. Directly comparable to Beacon's life sciences business: similar goal of replacing in-clinic EEG/PSG with remote, longitudinal brain-activity data for pharma-led trials in psychiatry and neurology.
  • Cambridge Cognition: Digital cognitive assessment and CNS clinical trial endpoint company serving biopharma. Comparable to Beacon's life sciences side as a vendor of objective, scalable brain/CNS endpoints (cognitive rather than EEG, but the same biopharma R&D buyer and biomarker-discovery value proposition).

Broad incumbents

  • Compumedics: Global sleep diagnostics and neurophysiology hardware and software company. Direct overlap with Beacon's SleepView/EEG business: PSG, HST, and EEG systems sold to sleep labs, hospitals, and research sites, with attached software and scoring services.
  • Nox Medical: Sleep diagnostics hardware and software (PSG, HSAT, AURA) company with strong presence in sleep labs and HST providers. Comparable to Beacon's home and lab sleep testing stack, particularly the CleveMed/SleepView business, and increasingly to Beacon's cloud platform strategy.
  • Natus Medical: Long-established neurodiagnostics and sleep diagnostics device maker with a broad portfolio of EEG, PSG, and HST hardware. Comparable to the CleveMed/SleepView side of Beacon in clinical-channel neurodiagnostic hardware, and to Beacon's PSG/EEG algorithm stack through Natus' competing clinical offerings.
  • Verily (an Alphabet company): Alphabet-owned precision health and sleep/brain health business (including the Verily Study Watch and earlier sleep efforts). Comparable to Beacon in its ambition to build a multi-modal, at-home, AI-driven brain/cardiac data platform for clinical research, but with vastly larger capital and distribution.
  • Itamar Medical (a ZOLL/ResMed company): Home sleep testing and cardiology diagnostics (WatchPAT) provider acquired by ZOLL/ResMed. Closely comparable to CleveMed/SleepView in the at-home HST category and to Beacon's direct-to-provider sleep diagnostics channel, with similar reimbursement and sleep physician buyer profiles.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Beacon Biosignals social profiles

Digital presence

Beacon Biosignals compliance and trust

Trust signal

Compliance6 records

Beacon Biosignals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Beacon Biosignals leadership team

Management profile

Number of profiles

Profiles17 records

Beacon Biosignals subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Beacon Biosignals funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Beacon Biosignals M&A and investment

M&A and investment

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Beacon Biosignals

What does Beacon Biosignals do?

Beacon Biosignals provides an end-to-end precision neuroscience platform that combines an FDA 510(k)-cleared at-home EEG headband (Waveband, formerly Dreem 3S) with a cloud-native AI/ML analytics stack (Beacon Datastore, Beacon HQ, SleepStage ML) and proprietary brain-activity foundation models to deliver EEG biomarkers, quantitative endpoints, and sleep diagnostics for CNS drug development and clinical care. The platform supports Phase 1-4 clinical trials for biopharmaceutical sponsors and is paired with a home sleep testing business (SleepView Monitor, SleepView Direct, SleepView Web Portal) acquired from CleveMed that serves sleep physicians, neurologists, and primary care providers.

Is Beacon Biosignals a public or private company?

Beacon Biosignals is a private company. It is classified as venture growth investor backed and is currently operating.

When was Beacon Biosignals founded?

Beacon Biosignals was founded in 2019. It employs 101 to 250 people.

Where is Beacon Biosignals based?

Beacon Biosignals is headquartered in Boston, United States, in the North America region.

How does Beacon Biosignals make money?

Five revenue lines are on record. SleepView Direct bundled study pricing is the primary driver. The others are sleepView Monitor hardware + SleepView Web Portal subscription, biopharma data licensing and milestone payments (Takeda model), clinical Study Operations and Scientific Services (professional services) and beacon Platform enterprise analytics (Datastore + Beacon HQ).

Who are Beacon Biosignals's main competitors?

Direct peers on record are iRhythm Technologies, Ceribell, ActiGraph, Cumulus Neuroscience and Cambridge Cognition. Broad incumbents are Compumedics, Nox Medical, Natus Medical, Verily (an Alphabet company) and Itamar Medical (a ZOLL/ResMed company).

Does Beacon Biosignals have an API?

No public API is recorded for Beacon Biosignals.

What industry is Beacon Biosignals in?

Beacon Biosignals's product category is Neurotechnology & Brain Health Analytics. Its primary akta.pro industry code is HLAGAEAB, Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry), with a secondary code of HLAAAMAC, Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays). Its NAICS code is 6215 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Longevity.TechnologyBeacon buys Snap to bring EEG to home sleep testsBeacon Biosignals acquired Snap Diagnostics, a home sleep testing provider, to expand its patient reach and enable EEG-based sleep testing in primary care from 2027. The deal more than doubles Beacon's patient reach, and Beacon plans to bring EEG-enabled home testing to more patients starting in 2027.Longevity.TechnologyBeacon Biosignals acquires Snap Diagnostics for home EEG sleep testingBeacon Biosignals acquired Snap Diagnostics, a home sleep testing provider operating in all 50 states. The deal more than doubles Beacon's patient reach and establishes a national channel for EEG-enabled home sleep testing starting in 2027. Beacon's FDA 510(k)-cleared Waveband headband measures brain electrical activity directly.Startup ResearcherBeacon Biosignals Acquires Snap Diagnostics to Expand Home Sleep TestingBeacon Biosignals acquired Snap Diagnostics on October 22, 2026, to expand home sleep testing across all 50 states. The deal more than doubles Beacon's patient reach and introduces EEG-enabled testing in 2027. Snap will remain a subsidiary with no changes to its services.Business & FinancialBeacon Biosignals Acquires Snap Diagnostics, Paving The Way For EEG-Enabled Home Sleep Testing In Every Care SettingBeacon Biosignals acquired Snap Diagnostics, a home sleep testing provider serving all 50 states, doubling its patient reach. The acquisition enables EEG-enabled home sleep testing starting in 2027, expanding access beyond sleep specialists. Beacon plans to apply its EEG and AI platform to broader clinical care, including neurodegenerative and psychiatric conditions.FinancialContent Business PageBeacon Biosignals Acquires Snap Diagnostics, Paving the Way for EEG-Enabled Home Sleep Testing in Every Care SettingBeacon Biosignals acquired Snap Diagnostics, a home sleep testing provider serving all 50 states, doubling its patient reach. The acquisition enables EEG-enabled home sleep testing starting in 2027, expanding access beyond sleep specialists. Beacon plans to apply its EEG and AI platform to broader clinical care, including neurodegenerative disease screening.GlobeNewswireBeacon Biosignals Acquires Snap Diagnostics, Paving the Way for EEG-Enabled Home Sleep Testing in Every Care SettingBeacon Biosignals acquired Snap Diagnostics, a home sleep testing provider serving all 50 states, doubling its patient reach. The acquisition enables EEG-enabled home sleep testing starting in 2027, expanding access beyond sleep specialists. Beacon plans to apply its EEG and AI platform to broader clinical care, including neurological and psychiatric conditions.Business & FinancialBeacon Biosignals Partners With Project Sleep To Shorten The Path To Diagnosis For People With Idiopathic Hypersomnia And NarcolepsyBeacon Biosignals announced a partnership with Project Sleep to shorten diagnostic delays for idiopathic hypersomnia and narcolepsy. The collaboration will use Beacon's AI-driven neurotechnology and Project Sleep's patient community to identify undiagnosed patients and support treatment pathways. They will begin joint work immediately, including Beacon's participation in Project Sleep's 7th annual Sleep Advocacy Forum on October 26, 2026.The future of tradingBeacon Biosignals Partners with Project Sleep to Shorten the Path to Diagnosis for People with Idiopathic Hypersomnia and NarcolepsyBeacon Biosignals announced a partnership with Project Sleep to shorten diagnostic delays for idiopathic hypersomnia and narcolepsy. The partnership aims to identify undiagnosed patients and support those already diagnosed, citing average wait times of 8-11 years for IH and 4-11 years for narcolepsy type 1. Beacon will participate in Project Sleep's 7th annual Sleep Advocacy Forum on October 26, 2026.Longevity.TechnologyBeacon Biosignals showcases advanced AI sleep tech and clinical data at SLEEP 2026Beacon Biosignals participated in SLEEP 2026, a sleep medicine conference, showcasing its AI-powered sleep analytics platform including automated sleep staging algorithms, machine learning-based arousal detection, and a large-scale EEG foundation model for multi-device analytics. The company also presented validation data for its Waveband device in hypersomnia disorders, developed in collaboration with Takeda, which featured in an oral presentation. The activity signals ongoing progress toward building clinically relevant evidence that could support future commercialization or partnership opportunities in sleep medicine and neurology.Mugglehead MagazineFive technologies moving from science fiction to reality: A Mugglehead roundupThis Mugglehead roundup profiles five emerging technologies moving from concept toward clinical or commercial deployment, spanning healthcare diagnostics, remote surgery, and nuclear energy. The article covers home sleep diagnostics through Beacon Biosignals' acquisition of CleveMed, microvascular heart disease assessment via CoroFlow, breath-based lung cancer screening from Owlstone Medical and Breath Diagnostics, remote robotic surgery involving Intuitive Surgical, Medtronic, Johnson & Johnson, and MicroPort MedBot's Toumai system, and Deep Fission's below-ground small modular reactor design. Each technology targets longstanding limitations in current practice—whether expanding access, improving diagnostic accuracy, or reducing infrastructure costs—with varying stages of commercialization ranging from early research to FDA-authorized procedures already performed across continents.